drugset / Trial / NCT01282151
TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is: * A multicenter, prospective, randomized, phase 3 trial. * To prove non-inferiority of Taxotere/Cisplatin compared to Pemetrexed/Cisplatin as a front line treatment of patients with non-squamous cell lung cancer. * 276 patients will be recruited.
Timeline
- Start
- 2011-07
- Primary completion
- 2013-12
- Completion
- 2014-12
Outcome
Outcome not reported
Stopped (Enrollment): “Difficulty in recruitment due to approval of maintenance pemetrexed treatment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 70 mg/m2 | — |